Gilead Sciences could rise nearly 30% as the biopharma industry gets back on its feet, Bank of America says
The biopharmaceutical sector is expected to bounce back this year, and Gilead Sciences could be a key beneficiary, according to Bank of America. Analyst Geoff Meacham upgraded Gilead to Buy…